ST. JOSEPH, Mich., Feb. 22 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that the Medical Biochemistry group at the Academic Medical Center, University of Amsterdam will join the MetaMiner Metabolic Diseases project from GeneGo. The MetaMiner program is focused on the fundamental understanding of human diseases at the level of disease pathways and causative gene-disease associations supported by a repository of OMICs data. Ongoing MetaMiner projects include Oncology, CNS, Cystic fibrosis and Stem cells.
"GeneGo provides unique, innovative reconstructions of disease pathways that are fundamentally important and required for the understanding of disease processes so we can find cures," said Milka Sokolovic, PhD, Medical Biochemistry, Academic Medical Center, Amsterdam. "We want to be a part of this innovation to have access to high quality resources to build pathways we need for our research programs that we will use to publish."
"The University of Amsterdam group is well known for their research on nutrition and fasting and we really welcome Milka's expertise in this area," said Julie Bryant, GeneGo's VP of Business Development. "This will be the first 'systems analysis' platform devoted specifically for metabolic diseases. We will start with the 'usual suspects' of type 2 diabetes and obesity and then move to other human diseases which significantly affect metabolism."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.1™, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.1™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.
For more information, please visit the company's web site at www.genego.com.
SOURCE GeneGo, Inc.Back to top
|SOURCE GeneGo, Inc.|
Copyright©2010 PR Newswire.
All rights reserved